Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 2
1971 2
1972 1
1973 1
1975 3
1976 2
1977 5
1979 1
1980 2
1981 1
1982 3
1984 4
1985 1
1987 1
1989 2
1991 1
1993 1
1995 2
2012 1
2013 5
2015 1
2016 3
2017 5
2018 2
2019 2
2020 7
2021 15
2022 18
2023 8
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Results by year

Filters applied: . Clear all
Page 1
Resistance to peptidoglycan-degrading enzymes.
Grishin AV, Karyagina AS, Vasina DV, Vasina IV, Gushchin VA, Lunin VG. Grishin AV, et al. Among authors: gushchin va. Crit Rev Microbiol. 2020 Nov;46(6):703-726. doi: 10.1080/1040841X.2020.1825333. Epub 2020 Sep 26. Crit Rev Microbiol. 2020. PMID: 32985279 Review.
Single-domain antibody delivery using an mRNA platform protects against lethal doses of botulinum neurotoxin A.
Panova EA, Kleymenov DA, Shcheblyakov DV, Bykonia EN, Mazunina EP, Dzharullaeva AS, Zolotar AN, Derkaev AA, Esmagambetov IB, Sorokin II, Usachev EV, Noskov AN, Ivanov IA, Zatsepin TS, Dmitriev SE, Gushchin VA, Naroditsky BS, Logunov DY, Gintsburg AL. Panova EA, et al. Among authors: gushchin va. Front Immunol. 2023 Feb 14;14:1098302. doi: 10.3389/fimmu.2023.1098302. eCollection 2023. Front Immunol. 2023. PMID: 36865543 Free PMC article.
Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents: an open-label, non-randomized, multicenter, phase 1/2, dose-escalation study.
Tukhvatulin AI, Dolzhikova IV, Dzharullaeva AS, Grousova DM, Kovyrshina AV, Zubkova OV, Zorkov ID, Iliukhina AA, Shelkov AY, Erokhova AS, Popova O, Ozharovskaia TA, Zrelkin DI, Izhaeva FM, Shcheblyakov DV, Esmagambetov IB, Tokarskaya EA, Nikitenko NA, Lubenets NL, Khadorich EA, Gushchin VA, Borzakova SN, Vlasova AV, Osmanov IM, Gorev VV, Naroditsky BS, Logunov DY, Gintsburg AL. Tukhvatulin AI, et al. Among authors: gushchin va. Front Immunol. 2023 Aug 1;14:1228461. doi: 10.3389/fimmu.2023.1228461. eCollection 2023. Front Immunol. 2023. PMID: 37600800 Free PMC article. Clinical Trial.
Microbiological Characteristics of Some Stations of Moscow Subway.
Pochtovyi AA, Vasina DV, Verdiev BI, Shchetinin AM, Yuzhakov AG, Ovchinnikov RS, Tkachuk AP, Gushchin VA, Gintsburg AL. Pochtovyi AA, et al. Among authors: gushchin va. Biology (Basel). 2022 Jan 21;11(2):170. doi: 10.3390/biology11020170. Biology (Basel). 2022. PMID: 35205037 Free PMC article.
In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1.
Pochtovyi AA, Kustova DD, Siniavin AE, Dolzhikova IV, Shidlovskaya EV, Shpakova OG, Vasilchenko LA, Glavatskaya AA, Kuznetsova NA, Iliukhina AA, Shelkov AY, Grinkevich OM, Komarov AG, Logunov DY, Gushchin VA, Gintsburg AL. Pochtovyi AA, et al. Among authors: gushchin va. Vaccines (Basel). 2023 Sep 28;11(10):1533. doi: 10.3390/vaccines11101533. Vaccines (Basel). 2023. PMID: 37896937 Free PMC article.
The rise and spread of the SARS-CoV-2 AY.122 lineage in Russia.
Klink GV, Safina KR, Nabieva E, Shvyrev N, Garushyants S, Alekseeva E, Komissarov AB, Danilenko DM, Pochtovyi AA, Divisenko EV, Vasilchenko LA, Shidlovskaya EV, Kuznetsova NA; Coronavirus Russian Genetics Initiative (CoRGI) Consortium; Speranskaya AS, Samoilov AE, Neverov AD, Popova AV, Fedonin GG; CRIE Consortium; Akimkin VG, Lioznov D, Gushchin VA, Shchur V, Bazykin GA. Klink GV, et al. Among authors: gushchin va. Virus Evol. 2022 Mar 5;8(1):veac017. doi: 10.1093/ve/veac017. eCollection 2022. Virus Evol. 2022. PMID: 35371558 Free PMC article.
Isolation and Characterisation of Alongshan Virus in Russia.
Kholodilov IS, Litov AG, Klimentov AS, Belova OA, Polienko AE, Nikitin NA, Shchetinin AM, Ivannikova AY, Bell-Sakyi L, Yakovlev AS, Bugmyrin SV, Bespyatova LA, Gmyl LV, Luchinina SV, Gmyl AP, Gushchin VA, Karganova GG. Kholodilov IS, et al. Among authors: gushchin va. Viruses. 2020 Mar 26;12(4):362. doi: 10.3390/v12040362. Viruses. 2020. PMID: 32224888 Free PMC article.
Features of the Humoral Response to Infection, Vaccination, and Revaccination during COVID-19.
Kombarova SY, Aleshkin AV, Novikova LI, Bochkareva SS, Zatevalov AM, Mekhtiev ER, Mizaeva TE, Basov AA, Borisova OY, Likhanskaya EI, Voropaeva EA, Urban YN, Mitrokhin SD, Shkoda AS, Gushchin VA, Sinyavin AE, Nikiforova MA, Lebedin YS, Karaulov AV. Kombarova SY, et al. Among authors: gushchin va. Bull Exp Biol Med. 2022 Oct;173(6):734-739. doi: 10.1007/s10517-022-05620-1. Epub 2022 Nov 2. Bull Exp Biol Med. 2022. PMID: 36322302 Free PMC article.
Antiviral Activity of N1,N3-Disubstituted Uracil Derivatives against SARS-CoV-2 Variants of Concern.
Siniavin AE, Novikov MS, Gushchin VA, Terechov AA, Ivanov IA, Paramonova MP, Gureeva ES, Russu LI, Kuznetsova NA, Shidlovskaya EV, Luyksaar SI, Vasina DV, Zolotov SA, Zigangirova NA, Logunov DY, Gintsburg AL. Siniavin AE, et al. Among authors: gushchin va. Int J Mol Sci. 2022 Sep 5;23(17):10171. doi: 10.3390/ijms231710171. Int J Mol Sci. 2022. PMID: 36077564 Free PMC article.
Guide RNA Design for CRISPR/Cas9-Mediated Potato Genome Editing.
Khromov AV, Gushchin VA, Timerbaev VI, Kalinina NO, Taliansky ME, Makarov VV. Khromov AV, et al. Among authors: gushchin va. Dokl Biochem Biophys. 2018 Mar;479(1):90-94. doi: 10.1134/S1607672918020084. Epub 2018 May 19. Dokl Biochem Biophys. 2018. PMID: 29779105
101 results